6th Annual Future of Clinical Trials

Jacob Fleming Conferences26 - 27 October 2010, Vienna, Austria.
Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success. Reveal, how to tailor clinical trials to the needs of the patients. Discuss the innovative methods of motivating patients and physicians. Learn from first hand experience, how to optimize patient recruitment & retention, and explore the patient pool in Russia and Southeastern Europe. Achieve the competitive advantage through increased partnering with academic centres of excellence, patient organizations and CROs.

Discuss with leading Pharma companies, what is the future of clinical trials & how to be prepared to succeed.

Key speakers:

  • Senior Vice President Global Clinical Operations, MerckSerono, Switzerland
  • Vice President Medical Affairs Global Diabetes Division, Sanofi Aventis, France
  • Deputy Head of Global Clinical Development Metabolism, Development Sub-Team Leader Dalcetrapib, Roche, Swizterland
  • VP R&D Science Policy, AstraZeneca, UK
  • Head Clinical Research, Novartis, Switzerland
  • Head Clinical Research, Novo Nordisk, Russia
  • Project Officer, VSOP, The Netherlands
  • Head of Biostatistics & Data Management, Global Clinical R&D, GSK Biologicals, Belgium
  • European AIDS Treatment Group (EATG), Germany
  • Chief Medical Officer Southern Europem, Novartis Vaccines & Diagnostics, Italy

Key topics:

  • New approaches to conducting clinical trials in a current dynamic and competitive environment
  • Examine key recruiting trends in Europe & Asia – exploit the patient pool and trials potential in the Southeastern Europe, Russia & Asian countries
  • Achieve competitive advantage through increased partnerships with academic centres of excellence, patient organizations & CROs
  • Gain first-hand information on PatientPartner project – how to establish partnership between stakeholders to the benefit of clinical trials and the treatment of patients in the future
  • Explore innovative methods of motivating investigators and patients
  • Understand the recent developments in the regulatory & legal environment
  • Best practices in designing a study protocol

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Clinical Development, Clinical Operations, Clinical Trials, Clinical Research, Patient Recruitment, Patient Retention, Site Management, Clinical Outsourcing, Sourcing Strategies, Medical Affairs, Contract Outsourcing, Clinical Strategy, Clinical Project Management, Regulatory Affairs, Clinical Research Associates, Clinical Research Organizations.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-future-of-clinical-trials?partner=worldpharmanews

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...